Please login to the form below

Not currently logged in
Email:
Password:

UK/Russian pharma firm launches

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano)

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano).

The company said it intends to support a 'unique humanitarian mission' with products to be priced in different areas based on the region's ability to pay.

Free drug donations will be available to countries in Africa based on the success of products sold Western Europe.

The launch of Pro Bono Bio comes at the same time as UK Prime Minister David Cameron's visit to Russia.

He said: "This is a great example of UK/Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."

As part of the company's development, Pro Bono Bio said it intends to build a manufacturing plant in the UK. A further facility is also planned for Moscow.

The company is to launch its first product Flexiseq, a nanotechnology based treatment for osteoarthritis, in the UK today, with further plans to release drugs for skin disorders in the coming months.

Other pipeline products for the company include blood factors for the treatment of haemophilia as well as antibiotics for the treatment of infections such as Clostridium difficile, MRSA and tuberculosis.

12th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics